GlassScriptPhysician profile
Sonia D Evans
NPI 1518473149
$4,422.84
in general payments reported to CMS, 2019-2025
31 companies · $645 in 2025
The $645 reported for 2025 was more than what 78% of Nurse Practitioner providers received nationally (typical 2025 total: $174).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $726 · 2022: $621 · 2023: $1,472 · 2024: $959 · 2025: $645.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,076.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,076.13 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amgen INC. | $696.15 | 2021-2025 | Evenity, Repatha, Otezla |
| Novo Nordisk INC | $678.22 | 2021-2025 | Wegovy, Ozempic, Rybelsus |
| Bayer Healthcare Pharmaceuticals INC. | $418.04 | 2022-2024 | |
| Astrazeneca Pharmaceuticals LP | $406.06 | 2022-2025 | Farxiga, Airsupra |
| Lilly USA, LLC | $373.92 | 2021-2025 | Mounjaro, Zepbound, Jardiance |
| Boehringer Ingelheim Pharmaceuticals, INC. | $253.72 | 2023-2025 | Jardiance, Synjardy, Tradjenta |
| Abbvie INC. | $237.49 | 2021-2023 | |
| Glaxosmithkline, LLC. | $223.96 | 2021-2025 | Trelegy Ellipta, Shingrix, Arexvy |
| Abbott Laboratories | $170.16 | 2021-2024 | Freestyle Libre |
| Sanofi-Aventis U.S. LLC | $124.78 | 2023 | |
| Pfizer INC. | $97.89 | 2023-2025 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $85.64 | 2023-2024 | Xifaxan, Trulance |
| Otsuka America Pharmaceutical, INC. | $82.88 | 2023-2025 | Rexulti |
| Biohaven Pharmaceuticals, INC. | $65.32 | 2021 | |
| Phathom Pharmaceuticals, INC. | $61.50 | 2024 | Voquezna |
Show all 31 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Antares Pharma, INC. | $45.34 | 2022-2024 | Xyosted |
| Dexcom, INC. | $42.55 | 2021-2023 | Dexcom G6 Transmitter |
| Janssen Pharmaceuticals, INC | $36.44 | 2021-2022 | |
| Astellas Pharma US INC | $36.34 | 2021-2023 | Veozah |
| Biogen, INC. | $33.20 | 2021 | |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $31.14 | 2024-2025 | Caplyta |
| Halozyme INC | $30.72 | 2023 | |
| Esperion Therapeutics, INC. | $29.89 | 2025 | Nexletol |
| E.R. Squibb & Sons, L.L.C. | $29.81 | 2021-2022 | |
| Exact Sciences Corporation | $29.30 | 2024 | Cologuard Collection Kit |
| Lundbeck LLC | $24.44 | 2023 | Rexulti |
| Vanda Pharmaceuticals INC. | $21.47 | 2025 | Fanapt |
| Boston Scientific Corporation | $15.65 | 2024 | Watchman Flx |
| Idorsia Pharmaceuticals US INC | $15.31 | 2023 | Quviviq |
| Biohaven Pharmaceutical Holding Company LTD. | $13.53 | 2022 | |
| Genentech USA, INC. | $11.98 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Sonia Evans listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.